Chronic Heart Failure - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Chronic Heart Failure - Pipeline Review, H2 2016

Chronic Heart Failure - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Chronic Heart Failure - Pipeline Review, H2 2016
Published Sep 30, 2016
156 pages — Published Sep 30, 2016
Price US$ 2,000.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chronic Heart Failure Pipeline Review, H2 2016, provides an overview of the Chronic Heart Failure (Cardiovascular) pipeline landscape.

Chronic heart failure is a serious condition caused by the heart failing to pump enough blood around the body at the right pressure. The symptoms develop gradually. Common symptoms are cough, fatigue, weakness, faintness, loss of appetite; need to urinate at night, shortness of breath, swollen (enlarged) liver or abdomen, swollen feet and ankles and weight gain. Risk factors that contribute to heart failure are high blood pressure, coronary artery disease, heart attack, diabetes and alcohol use.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chronic Heart Failure Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Chronic Heart Failure (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Chronic Heart Failure (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Chronic Heart Failure and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Discovery stages are 9, 11, 2 and 1 respectively for Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively for Chronic Heart Failure.

Chronic Heart Failure (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Chronic Heart Failure (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Chronic Heart Failure (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Chronic Heart Failure (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Chronic Heart Failure (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all th

  
Source:
Document ID
GMDHC8517IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents26
  List of Tables61
  List of Figures71
Introduction81
  Global Markets Direct Report Coverage81
Chronic Heart Failure Overview91
Therapeutics Development102
  Pipeline Products for Chronic Heart Failure Overview101
  Pipeline Products for Chronic Heart Failure Comparative Analysis111
Chronic Heart Failure Therapeutics under Development by Companies122
Chronic Heart Failure Therapeutics under Investigation by Universities/Institutes141
Chronic Heart Failure Pipeline Products Glance153
  Late Stage Products151
  Clinical Stage Products161
  Early Stage Products171
Chronic Heart Failure Products under Development by Companies181
Chronic Heart Failure Products under Investigation by Universities/Institutes191
Chronic Heart Failure Companies Involved in Therapeutics Development2018
  Amgen Inc.201
  AnGes MG, Inc.211
  AstraZeneca Plc221
  Bayer AG231
  Capricor Therapeutics, Inc.241
  Celyad SA251
  Juventas Therapeutics, Inc.261
  Laboratoires Pierre Fabre SA271
  Les Laboratoires Servier SAS281
  Mast Therapeutics, Inc.291
  Mesoblast Limited301
  Novartis AG311
  Pfizer Inc.321
  scPharmaceuticals Inc331
  Stemedica Cell Technologies, Inc.341
  Theravance Biopharma, Inc.351
  Vichem Chemie Research Ltd.361
  Zensun (Shanghai) Sci &Tech Co., Ltd.371
Chronic Heart Failure Therapeutics Assessment3810
  Assessment by Monotherapy Products381
  Assessment by Combination Products391
  Assessment by Target402
  Assessment by Mechanism of Action422
  Assessment by Route of Administration442
  Assessment by Molecule Type462
Drug Profiles4891
  (sacubitril + valsartan) Drug Profile485
  beperminogene perplasmid Drug Profile535
  C3BSCQR-1 Drug Profile585
  cenderitide Drug Profile633
  CLR-325 Drug Profile661
  dapagliflozin propanediol Drug Profile677
  F-373280 Drug Profile741
  furosemide Drug Profile752
  ivabradine hydrochloride Drug Profile772
  JVS-100 Drug Profile794
  L-2286 Drug Profile831
  MPC-150IM Drug Profile845
  neladenoson bialanate Drug Profile891
  Neucardin Drug Profile903
  omecamtiv mecarbil MR Drug Profile937
  rivaroxaban Drug Profile10014
  S-38844 Drug Profile1141
  serelaxin Drug Profile1154
  sildenafil citrate Drug Profile1192
  Small Molecules for Chronic Heart Failure Drug Profile1211
  Stem Cell Therapy for Bacterial Sepsis, Cardiovascular Disease, CNS Disorders, Metabolic Disorders, Respiratory Disease and Toxicology Drug Profile1226
  Synthetic Peptide to Activate Erythropoietin Receptor for Cardiovascular Diseases Drug Profile1281
  TD-1439 Drug Profile1291
  vepoloxamer Drug Profile1308
  vericiguat Drug Profile1381
Chronic Heart Failure Dormant Projects1392
Chronic Heart Failure Discontinued Products1411
Chronic Heart Failure Product Development Milestones14213
  Featured News &Press Releases1421
    Sep 19, 2016: Important new analysis shows that Novartis Entresto is associated with higher relative health-related quality of life scores among HFrEF patients1421
    Sep 19, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at the HFSA Annual Scientific Meeting1431
    Sep 12, 2016: AstraZeneca announces two new phase IIIb trials for Forxiga in chronic kidney disease and chronic heart failure1441
    Sep 09, 2016: Cytokinetics Announces Additional Results From COSMIC-HF to Be Presented at the HFSA Annual Scientific Meeting1441
    Sep 01, 2016: Cytokinetics and Amgen to Advance Omecamtiv Mecarbil to Phase 3 Clinical Development1451
    Aug 28, 2016: CardioCell Reports Positive Results From the First Phase IIa Clinical Trial Using IV Administration of Stem Cells for Chronic Heart Failure Indications1452
    Jul 01, 2016: Mesoblast Provides Update On Heart Failure Trial And Funding Of Clinical Operations1471
    Jun 28, 2016: Celyad Announces Results for the CHART-1 Phase III Clinical Trial Evaluating C-Cure(R) Cell Therapy1481
    Jun 22, 2016: Timely use of Novartis Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology1491
    Jun 14, 2016: Mesoblast Provides Update On Global Heart Failure Program1501
    May 23, 2016: Cytokinetics Announces Presentation of Additional Results From COSMIC-HF at Heart Failure 2016 Congress1511
    May 23, 2016: Results of Vepoloxamer Nonclinical Studies in Advanced Heart Failure Presented at European Society of Cardiology 3rd World Congress on Acute Heart Failure1511
    May 13, 2016: Cytokinetics Announces Additional COSMIC-HF Results to Be Presented at Heart Failure 20161521
    Apr 26, 2016: NICE gives green light to new drug set to benefit 100,000 people with common heart condition1531
    Apr 26, 2016: Celyad receives certification for C-Cure non-clinical data from the European Medicines Agency1541
Appendix1552
  Methodology1551
  Coverage1551
  Secondary Research1551
  Primary Research1551
  Expert Panel Validation1551
  Contact Us1551
  Disclaimer1561

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Chronic Heart Failure - Pipeline Review, H2 2016" Sep 30, 2016. Alacra Store. Nov 15, 2026. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Heart-Failure-Pipeline-Review-H2-2016-2088-16644>
  
APA:
Global Markets Direct - Market Research. (2016). Chronic Heart Failure - Pipeline Review, H2 2016 Sep 30, 2016. New York, NY: Alacra Store. Retrieved Nov 15, 2026 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Chronic-Heart-Failure-Pipeline-Review-H2-2016-2088-16644>
  
US$ 2,000.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.